PHARMAC considering funding new medicines for lung cancer

PHARMAC

6 July 2022 - PHARMAC is seeking proposals from pharmaceutical suppliers for medicines that could treat New Zealanders with lung cancer.

“Lung cancer is one of the most commonly diagnosed cancers in Aotearoa and it is the leading cause of cancer-related mortality,” says PHARMAC’s Chief Executive, Sarah Fitt. “The medicines we will be evaluating are a type of immunotherapy called immune checkpoint inhibitors.”

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder